Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

507 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia.
Raffoux E, Rousselot P, Poupon J, Daniel MT, Cassinat B, Delarue R, Taksin AL, Réa D, Buzyn A, Tibi A, Lebbé G, Cimerman P, Chomienne C, Fermand JP, de Thé H, Degos L, Hermine O, Dombret H. Raffoux E, et al. Among authors: rea d. J Clin Oncol. 2003 Jun 15;21(12):2326-34. doi: 10.1200/JCO.2003.01.149. J Clin Oncol. 2003. PMID: 12805334 Clinical Trial.
Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study.
de Labarthe A, Rousselot P, Huguet-Rigal F, Delabesse E, Witz F, Maury S, Réa D, Cayuela JM, Vekemans MC, Reman O, Buzyn A, Pigneux A, Escoffre M, Chalandon Y, MacIntyre E, Lhéritier V, Vernant JP, Thomas X, Ifrah N, Dombret H; Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL). de Labarthe A, et al. Among authors: rea d. Blood. 2007 Feb 15;109(4):1408-13. doi: 10.1182/blood-2006-03-011908. Epub 2006 Oct 24. Blood. 2007. PMID: 17062730 Free article. Clinical Trial.
Undetectable molecular residual disease after omacetaxine and nilotinib combination therapy in an imatinib-resistant chronic myeloid leukaemia patient harbouring the BCR-ABL1 T315I gatekeeper mutation.
Coude MM, Luycx O, Cariou ME, Maarek O, Dombret H, Cayuela JM, Rea D. Coude MM, et al. Among authors: rea d. Br J Haematol. 2012 May;157(3):407-10. doi: 10.1111/j.1365-2141.2011.09016.x. Epub 2012 Jan 9. Br J Haematol. 2012. PMID: 22225474 Free article. No abstract available.
Curing chronic myeloid leukemia.
Rea D, Rousselot P, Guilhot J, Guilhot F, Mahon FX. Rea D, et al. Curr Hematol Malig Rep. 2012 Jun;7(2):103-8. doi: 10.1007/s11899-012-0117-2. Curr Hematol Malig Rep. 2012. PMID: 22410764 Review.
Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study.
Tanguy-Schmidt A, Rousselot P, Chalandon Y, Cayuela JM, Hayette S, Vekemans MC, Escoffre M, Huguet F, Réa D, Delannoy A, Cahn JY, Vernant JP, Ifrah N, Dombret H, Thomas X. Tanguy-Schmidt A, et al. Among authors: rea d. Biol Blood Marrow Transplant. 2013 Jan;19(1):150-5. doi: 10.1016/j.bbmt.2012.08.021. Epub 2012 Sep 6. Biol Blood Marrow Transplant. 2013. PMID: 22960387 Free article. Clinical Trial.
507 results